Kyverna Therapeutics (NASDAQ:KYTX) Price Target Lowered to $24.00 at Wells Fargo & Company

Kyverna Therapeutics (NASDAQ:KYTX) had its price objective trimmed by Wells Fargo & Company from $44.00 to $24.00 in a research report report published on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other equities research analysts have also commented on KYTX. UBS Group began coverage on Kyverna Therapeutics in a research report on Thursday, October 10th. They issued a “buy” rating and a $13.00 price target on the stock. Rodman & Renshaw began coverage on Kyverna Therapeutics in a research report on Wednesday, October 9th. They issued a “buy” rating and a $16.00 price target on the stock. JPMorgan Chase & Co. cut their target price on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. Finally, HC Wainwright restated a “neutral” rating and set a $7.00 target price on shares of Kyverna Therapeutics in a research report on Thursday, September 19th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Kyverna Therapeutics currently has a consensus rating of “Buy” and an average target price of $25.86.

Kyverna Therapeutics Trading Up 1.3 %

NASDAQ KYTX opened at $4.41 on Friday. The business’s 50-day moving average price is $5.46 and its two-hundred day moving average price is $8.42. Kyverna Therapeutics has a 12 month low of $4.30 and a 12 month high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.01. The company had revenue of $0.01 million during the quarter. As a group, sell-side analysts anticipate that Kyverna Therapeutics will post -3.31 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC acquired a new position in Kyverna Therapeutics during the 3rd quarter worth approximately $33,000. DekaBank Deutsche Girozentrale acquired a new position in Kyverna Therapeutics during the 1st quarter worth approximately $181,000. Creative Planning acquired a new position in Kyverna Therapeutics during the 3rd quarter worth approximately $54,000. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Kyverna Therapeutics in the first quarter worth approximately $313,000. Finally, Federated Hermes Inc. purchased a new stake in shares of Kyverna Therapeutics in the second quarter worth approximately $120,000. 18.08% of the stock is owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.